MYOMO, INC. - 10-Q Summary (Q2 2024)
Business Context and Reporting Period
Company: MYOMO, INC. (Ticker: MYO)
Reporting Period: Quarter ended June 30, 2024 (Q2 2024)
Business Overview: Myomo is a wearable medical robotics company developing myoelectric orthotics (MyoPro) for patients with neuromuscular disorders. The company operates primarily in the United States, with significant revenue derived from direct billing to patients and reimbursement from Medicare Part B and commercial insurers. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $7.52 million | $5.96 million | $11.28 million | $9.41 million |
| Product Revenue | $7.52 million | $4.24 million | $11.28 million | $7.69 million |
| Gross Profit | $5.33 million | $4.28 million | $7.62 million | $6.59 million |
| Gross Margin | 70.8% | 71.8% | 67.6% | 70.1% |
| Net Loss | $(1.12) million | $(1.01) million | $(4.96) million | $(3.66) million |
| Net Loss Per Share (Diluted) | $(0.03) | $(0.04) | $(0.13) | $(0.14) |
| Cash & Equivalents | $5.85 million (as of June 30, 2024) | |||
| Short-term Investments | ||||
| Total Liquidity | $8.98 million | |||
| Working Capital | $8.68 million | |||
| Accumulated Deficit | $(101.89) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 26% quarter-over-quarter (Q2 2024 vs. Q2 2023) and 20% year-to-date. Product revenue grew 77% in Q2 and 47% YTD, driven by increased deliveries to Medicare Part B patients and higher average selling prices following new CMS fee schedules effective April 1, 2024.
- Operating Expenses: Total operating expenses increased 20% in Q2 and 22% YTD.
- R&D: Increased 79% in Q2 and 89% YTD due to added headcount for engineering and product development.
- Selling, Clinical & Marketing: Increased 22% in Q2 and 19% YTD, primarily due to higher payroll costs to support clinical capacity for Medicare patients.
- G&A: Increased 4% in Q2 and 10% YTD, driven by increased headcount in reimbursement and HR functions.
- License Revenue: License revenue was $0 in Q2 2024 compared to $1.71 million in Q2 2023, as the initial license fee from the China joint venture was fully recognized in the prior year.
- Cash Flow: Net cash used in operating activities increased to $5.16 million for the six months ended June 30, 2024, compared to $2.10 million in the prior year period, reflecting higher operational spending and inventory buildup.
Guidance, Outlook, and Risks
- Outlook: Management believes it can achieve cash flow breakeven on a quarterly basis by the fourth quarter of 2024, contingent on supply chain stability and the ability to meet volume requirements for Medicare Part B patients.
- Capital Resources: The company raised approximately $5.4 million in a registered direct offering in January 2024. On July 11, 2024 (subsequent to period end), the company secured a $4.0 million revolving line of credit against eligible accounts receivable from Silicon Valley Bank.
- Key Risks:
- Reimbursement Concentration: Significant reliance on a single U.S. insurance payer (20-24% of product revenue) and Medicare Part B (35-47% of product revenue). Adverse changes in reimbursement policies could materially impact the business.
- Going Concern: The company has a history of operating losses and an accumulated deficit of $101.9 million. While management believes current cash and the new line of credit are sufficient for the next 12 months, substantial doubt exists regarding the ability to continue as a going concern without achieving breakeven or securing additional capital.
- Supply Chain: Dependence on a single third-party manufacturer (Cogmedix) for key subassemblies and limited suppliers for components creates potential disruption risks.
- Regulatory: Subject to extensive FDA and CMS regulations; changes in coverage determinations or device classification could restrict market access.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $8.98 million liquidity position against the burn rate of ~$5.2 million per six months to confirm the Q4 2024 breakeven target.
- Reimbursement Stability: Monitor the status of claims and appeals with the concentrated commercial insurer representing ~20% of revenue, as post-service denials have occurred historically.
- Medicare Volume: Assess the actual volume of Medicare Part B deliveries against the company's capacity to fabricate and fit devices, as this is the primary growth driver.
- Debt Covenants: Review the terms of the new $4.0 million line of credit, specifically the borrowing base (80% of eligible receivables) and interest rates (Prime + 0.5% or 8.5%, whichever is higher).
- Inventory Levels: Note the increase in inventory to $2.60 million (from $1.80 million at year-end 2023) and monitor for potential write-downs if sales volume does not meet expectations.